Clinical Report: Efficacy of Brolucizumab for Proliferative Diabetic Retinopathy
Overview
The CONDOR trial evaluated the efficacy and safety of brolucizumab versus panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR). The study was a phase 3, multicenter, randomized clinical trial conducted over 54 weeks, involving 689 participants.
Background
Diabetic retinopathy is a significant cause of preventable blindness, affecting a substantial portion of the diabetic population. Traditional treatment with PRP has known complications, prompting interest in alternative therapies such as anti-VEGF agents. Brolucizumab is an anti-VEGF agent with a low molecular weight, allowing for a greater volume of drug delivery.
Data Highlights
Study
Participants
Intervention
Duration
Primary Endpoint
CONDOR
689
Brolucizumab vs PRP
54 weeks
Noninferiority
Key Findings
Brolucizumab demonstrated noninferiority to PRP in treating PDR at 54 weeks.
The trial included treatment-naïve patients without prior PRP treatment.
Brolucizumab allows for a greater volume of drug delivery due to its low molecular weight.
CONDOR was conducted across 16 countries, enhancing the diversity of the study population.
Clinical Implications
Clinicians should consider the findings from the CONDOR trial when evaluating treatment options for PDR.
Conclusion
The CONDOR trial provides insights into the efficacy of brolucizumab for PDR.
by Sebastian Wolf, Youxin Chen, Xiaorong Li, Masahiko Shimura, Taiji Sakamoto, Charles C. Wykoff, Andres Emanuelli, Hani Salehi-Had, Kang Yan, Lidija Kovacic, Yongsoo Kim
A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.
